--- title: "Novo Nordisk's European stock surged 9% as competitors canceled their generic Wegovy weight loss drug projects" description: "Novo Nordisk's stock price rebounded over 8%, primarily due to the telemedicine company Hims & Hers withdrawing its low-cost generic weight loss drug plan under regulatory pressure, alleviating market" type: "news" locale: "en" url: "https://longbridge.com/en/news/275311297.md" published_at: "2026-02-09T11:48:08.000Z" --- # Novo Nordisk's European stock surged 9% as competitors canceled their generic Wegovy weight loss drug projects > Novo Nordisk's stock price rebounded over 8%, primarily due to the telemedicine company Hims & Hers withdrawing its low-cost generic weight loss drug plan under regulatory pressure, alleviating market concerns about GLP-1 drugs being replaced by cheaper alternatives. However, the company still faces "unprecedented pricing pressure," with its market value shrinking by nearly two-thirds from its peak in 2024, and competition from rivals like Eli Lilly and long-term pricing challenges remain severe Novo Nordisk's stock price continues to rebound as telemedicine company Hims & Hers Health Inc (hereinafter referred to as Hims & Hers) has withdrawn its plan to launch a low-cost generic weight loss drug due to regulatory and legal pressures. This news significantly alleviated market concerns about Novo Nordisk's core products facing competition from cheap generics, reinforcing its moat in the GLP-1 drug market. Novo Nordisk's stock, listed in Frankfurt, rose over 8% on Monday, continuing the rebound trend from last Friday. Previously, Hims & Hers attempted to launch a compound weight loss drug based on semaglutide at a price of only $49 last Thursday. However, after facing legal threats and regulatory pressure from Novo Nordisk and the U.S. Food and Drug Administration (FDA), the company announced on Saturday that it would stop offering the treatment. **** Hims & Hers stated that this decision was made after "constructive dialogue" with stakeholders. This incident marks a tightening stance from regulators on unauthorized compound GLP-1 drugs. Last Friday, FDA Director Marty Makary signaled a crackdown on such drugs, which led to a more than 5% rebound in Novo Nordisk's stock that day. Despite the short-term surge in stock price, Novo Nordisk still faces fierce competition from Eli Lilly and ongoing challenges from other low-cost compound alternatives in the market. The company warned of "unprecedented pricing pressure" in its annual financial report released last week, causing its stock to plummet by 17% at one point. Since its market value peaked in June 2024, the company's market capitalization has shrunk by nearly two-thirds. ## **Tightening Regulations and Competitor Withdrawal** The $49 compound weight loss drug that Hims & Hers attempted to launch has semaglutide as its core ingredient, which is also the key component of Novo Nordisk's blockbuster drugs Wegovy and Ozempic. The product faced strong opposition from the Danish pharmaceutical company and regulatory agencies as soon as it was announced. According to Reuters, after Novo Nordisk and the FDA issued legal and regulatory threats, Hims & Hers quickly changed its stance over the past weekend. The company stated on Saturday that **it has decided to stop offering the treatment drug.** This withdrawal directly contributed to Novo Nordisk's rise in the Frankfurt stock market on Monday. Prior to this, FDA Director Marty Makary's statements about cracking down on unauthorized compound GLP-1 drugs had already injected a dose of confidence into the market. Such compound drugs have long been viewed as a major threat to Novo Nordisk's pricing power in the weight loss and diabetes markets. Influenced by this regulatory shift, Novo Nordisk's stock had already rebounded over 5% last Friday. ## **Pressure from Price Wars Remains** Although regulatory intervention has temporarily curbed the impact of specific low-cost generics, Novo Nordisk's market environment remains challenging. In addition to dealing with challengers like Hims & Hers attempting to enter the market with compound drugs, the company must also confront strong competition from major competitor Eli Lilly In the annual financial report released last week, Novo Nordisk issued a clear warning to investors, stating that the company is facing "unprecedented pricing pressure." This pessimistic outlook directly triggered panic among investors, causing its stock price to plummet by 17% after the report was released. **The market is generally concerned that, with more competitors entering and alternative therapies emerging, the previously high-profit weight loss drug market will fall into a brutal price war.** ## **Significant Shrinkage in Market Value** This series of market fluctuations highlights Novo Nordisk's currently fragile valuation foundation. Once a darling of the market, Novo Nordisk's market value peaked in June 2024. However, hampered by intensified competition and pricing pressure, the company's stock price has significantly declined since then, with its market value evaporating by nearly two-thirds from its peak. Although the withdrawal of competitors from generic drug projects has provided a short-term boost to the stock price, whether it can reverse the long-term downward trend still depends on how the company maintains the competitiveness and pricing power of its products in an increasingly crowded field ### Related Stocks - [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 诺和诺德公司能否在 GLP-1 淘金热中助力将 10 万美元变成 100 万美元？ | 这将是一次近乎奇迹般的收益 | [Link](https://longbridge.com/en/news/276843492.md) | | “彻底失望”！德银首次下调诺和诺德评级 | 德意志银行首次下调诺和诺德股票评级至 “持有”，因其减肥药 CagriSema 在临床试验中表现不佳，导致市场抛售，股价暴跌 16%。摩根大通也下调评级并大幅削减销售预期，华尔街对该股的看涨比例降至数年最低，显示出对诺和诺德中期前景的悲观情 | [Link](https://longbridge.com/en/news/276727300.md) | | 关键事实：诺和诺德公司在 CagriSema 上面临挑战；计划进行 350 亿美元的并购 | 摩根大通的分析师对 CagriSema 的表现不佳表示担忧，这可能会影响诺和诺德在竞争激烈的肥胖治疗领域的需求和长期销售。诺和诺德预计今年将拨出多达 350 亿美元用于潜在的并购，原因是 CagriSema 的试验结果令人失望。诺和诺德承认 | [Link](https://longbridge.com/en/news/276670594.md) | | Jefferies 维持对诺和诺德公司 (0QIU) 的持有评级 | Jefferies 分析师 Michael Leuchten 对诺和诺德公司（0QIU）维持了持有评级，目标价为 275.00 丹麦克朗，而该股收盘价为 251.40 丹麦克朗。Leuchten 负责医疗保健行业的研究，平均回报率为-4.5 | [Link](https://longbridge.com/en/news/276747748.md) | | 诺和诺德明年大幅下调减肥神药在美售价，降幅最高 50% | 诺和诺德宣布将司美格鲁肽系列药物美国月标价统一降至 675 美元，降幅最高 50%，明年 1 月生效，旨在应对礼来竞争与市场压力。消息公布后美股盘前跌 3%，本周因新药数据不佳已累跌 19%。降价主要惠及高免赔额计划参保人，与 Medica | [Link](https://longbridge.com/en/news/276745048.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.